Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of momelotinib in myelofibrosis
jRCT1071250088Recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mivavotinib in myelofibrosis (MF), sponsored by GSK. Primary endpoint: Rolling transfusion independence rate at 24 weeks. Started Oct 2025; status: recruiting.
02
Drugs
mivavotinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on jRCT1071250088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071250088.